Mazdutide: Dual GLP-1 & Glucagon Agonist

The content on this page is for general informational and educational purposes only and is not intended as medical advice, a recommendation, or an endorsement of any specific medication, treatment, or health product. Always consult a qualified healthcare provider before making decisions about medications, supplements, or changes to your health regimen. BodySpec does not prescribe, dispense, promote, offer, sell, or facilitate access to any of the pharmaceutical products discussed below.

Have you ever wondered if a medication could curb appetite and enhance energy expenditure at the same time?

Mazdutide is a medication that targets two hormone systems in your body—one that helps you feel full after eating and another that boosts your calorie burn—to reduce hunger and increase metabolic rate. Clinical studies show this approach can lead to meaningful weight loss, improvements in insulin resistance and weight management, and reductions in cholesterol levels (Ji et al., 2023).

Engaging both satiety and energy circuits quietly reshapes how your body manages calories and fat storage, influencing the balance of subcutaneous and visceral fat.

How Mazdutide Works: Dual Receptor Agonism

Mazdutide binds GLP-1 receptors in the brain and glucagon receptors in tissues including the liver. Activating GLP-1 receptors slows gastric emptying and supports insulin release, which helps curb appetite. Meanwhile, activating glucagon receptors prompts the liver to oxidize fatty acids and produce less fat, raising overall energy expenditure (Deng et al., 2026).

Clinical Trial Evidence: Efficacy and Safety

Efficacy Results

In a major Phase III trial, people taking weekly mazdutide injections lost 16.65% of body weight after 60 weeks versus 1.5% with placebo. In total, 84.3% of participants achieved at least a 5% weight reduction, compared to 33.1% in the placebo group (Gao et al., 2026).

Safety and Tolerability

Gastrointestinal events—vomiting (53.1%), nausea (46.9%), and diarrhea (39.4%)—were the most common side effects. Most were mild to moderate and occurred primarily during the initial dose-escalation period. Serious adverse events occurred in 7.2% of the mazdutide group versus 5.2% on placebo, and 2.9% discontinued treatment due to adverse events, versus 0% on placebo (de Souza, 2026).

Regulatory Landscape and Development Status

In June 2025, China’s National Medical Products Administration approved mazdutide for chronic weight management (Innovent, 2025). Regulatory submissions are underway in other regions.

Practical Considerations for Side-Effect Management

In the GLORY-2 Phase III trial, gastrointestinal events occurred primarily during the initial dose-escalation period (de Souza, 2026). Patients should discuss strategies—like small, frequent meals or anti-nausea support—with their healthcare provider to manage GI symptoms.

Comparative Context: Other GLP-1 Therapies

Indirect comparisons place mazdutide’s weight loss in the same range as semaglutide 2.4 mg (14.9% at 68 weeks). Tirzepatide 15 mg showed a larger reduction (20.9% at 72 weeks) in a separate trial (Wilding et al., 2021; Jastreboff et al., 2022). Direct head-to-head data are not yet available.

Conclusion

Mazdutide’s dual-agonist mechanism represents a novel approach to weight reduction and metabolic regulation. Regardless of the intervention—diet, exercise, or pharmacotherapy—a DEXA scan provides precise measurements of fat mass, lean mass, and bone density, helping you understand changes in your body composition over time. To learn more, explore the benefits of a DEXA scan for bone, fat, and muscle analysis and discover its accuracy. When you’re ready for detailed insights, consider scheduling a BodySpec DEXA scan to get an accurate picture of your body composition.